Skip to main content

Haemophilia B

Observatory of Patients With Haemophilia B Treated by IdElvion®
NCT05086575 | Observational

OrPHEe is a non-interventional, prospective and national study which aim is to record real life data in haemophilia B French patients treated with Idelvion® to confirm the efficacy and safety of this product established in clinical development studies.

Trial Information
28 Sites
100 Participants
Recruiting

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

CHU Amiens Picardie
Amiens,France,31059
CH Annecy Genevois
Annecy,France
CHRU Besanon
Besançon,France
CHU Bordeaux Hpital Pellegrin
Bordeaux,France
CHRU Brest
Brest,France
CHU Caen
Caen,France
CHU ClermontFerrand
Clermont-Ferrand,France
CHU Dijon
Dijon,France
Hpital Simone Veil
Eaubonne,France
CHU de Grenoble
Grenoble,France
CRCMHC Hpital Kremlin Bictre
Le Kremlin-Bicêtre,France
CH du Mans
Le Mans,France
CHRU Lille
Lille,France
CHU de Limoges
Limoges,France
Hpital Edouard Herriot
Lyon,France
CHU Montpellier
Montpellier,France
CHRU Nancy
Nancy,France
CHU Nantes
Nantes,France
CHU Nice
Nice,France
Hpital Necker Enfants Malades
Paris,France
CHU de Reims
Reims,France
CHU Rennes
Rennes,France
CHU Rouen
Rouen,France
CHU SaintEtienne
Saint-Étienne,France
CHRU Strasbourg
Strasbourg,France
CHU Toulouse
Toulouse,France
CHU Tours
Tours,France
Hpital Andr Mignot CH Versailles
Versailles,France

Study Eligibility Criteria

  • Have agreed to participate in the observatory after receiving written information on the purpose of the study and the personal data to be collected (agreement of parents for under-age patients);
  • Present with haemophilia B and are currently being treated or have previously been treated with Idelvion® as a long-term prophylactic treatment, on-demand treatment or short-term treatment for surgical procedures or to cover periods with a high-risk of bleeding.
  • Do not have FIX targeted antibodies at the time of the inclusion visit
  • Refusal by the patient or his/her legal representative to participate in the study;
  • Existence of a contraindication to the use of Idelvion® treatment (known hypersensitivity to FIX or hamster proteins);
  • Simultaneous participation in an interventional clinical study on a drug

Additional Studies

Additional studies can be found at ClinicalTrials.gov